Extendicare (TSE:EXE – Get Free Report) will be releasing its earnings data after the market closes on Tuesday, November 12th.
Extendicare (TSE:EXE – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported C$0.29 EPS for the quarter. Extendicare had a net margin of 4.28% and a return on equity of 60.00%. The firm had revenue of C$348.48 million during the quarter, compared to analyst estimates of C$360.20 million.
Extendicare Price Performance
Shares of TSE EXE opened at C$9.12 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 0.60 and a debt-to-equity ratio of 305.80. The company has a market capitalization of C$761.25 million, a PE ratio of 13.41 and a beta of 1.26. The stock’s 50 day moving average price is C$9.10 and its 200-day moving average price is C$8.03. Extendicare has a twelve month low of C$5.75 and a twelve month high of C$9.52.
Extendicare Dividend Announcement
Wall Street Analyst Weigh In
EXE has been the topic of several research reports. Royal Bank of Canada lifted their price objective on shares of Extendicare from C$8.50 to C$9.50 in a research report on Monday, August 19th. TD Securities increased their price objective on Extendicare from C$9.00 to C$9.50 and gave the company a “hold” rating in a report on Wednesday, September 4th.
Get Our Latest Stock Analysis on Extendicare
About Extendicare
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Featured Articles
- Five stocks we like better than Extendicare
- The Risks of Owning Bonds
- Intel: Is Now the Time to Be Brave?Â
- Are Penny Stocks a Good Fit for Your Portfolio?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.